Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adam Schmuckler

Physician Assistant, Medical Columbia, MD Physician Assistant

NPI 1902903990 CMS profile 10595709

10710 Charter Dr, Suite G020, Columbia, MD 21044

Open in the dashboard

General payments

$17,081

512 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Schmuckler of Columbia, MD is reported in the CMS Open Payments database as having received $17,081 across 512 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,262 159
2024 General $3,486 133
2023 General $2,575 96
2022 General $6,019 94
2021 General $738 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Schmuckler
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Adam Schmuckler were reported at $4,262. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Adam Schmuckler Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $738 $156 $41–$563 $132
2022 $6,019 $185 $55–$649 $149
2023 $2,575 $199 $58–$717 $160
2024 $3,486 $206 $62–$740 $164
2025 $4,262 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Rigel Pharmaceuticals, Inc. $3,285 10 payments
  2. E.R. Squibb & Sons, L.L.C. $1,345 25 payments
  3. Janssen Biotech, Inc. $1,193 26 payments
  4. Novartis Pharmaceuticals Corporation $1,177 52 payments
  5. AstraZeneca Pharmaceuticals LP $987 35 payments
  6. Pfizer Inc. $833 36 payments
  7. Daiichi Sankyo Inc. $516 18 payments
  8. Genentech USA, Inc. $450 20 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $433 17 payments
  10. Merck Sharp & Dohme Corporation $414 18 payments
  11. Other $6,447 255 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,540 507 payments
  2. Consulting Fee $3,405 2 payments
  3. Education $136 3 payments
Products named General payments · program years 2021–2025
  1. Tavalisse $3,285 10 payments
  2. ERLEADA $510 10 payments
  3. REBLOZYL $423 6 payments
  4. KEYTRUDA $414 18 payments
  5. CALQUENCE $359 8 payments
  6. DARZALEX $355 9 payments
  7. ENHERTU $354 13 payments
  8. BRUKINSA $330 6 payments
  9. JAKAFI $310 13 payments
  10. Nubeqa $306 10 payments
  11. Other $13,210 542 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,075

Median for Physician Assistant: 241

Drug cost

$3,167,115

Median for Physician Assistant: $4,110

Branded share of claims

44.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brukinsa Zanubrutinib Brand 41 $616,549
Ninlaro Ixazomib Citrate Brand 39 $524,041
Imbruvica Ibrutinib Brand 28 $463,154
Jakafi Ruxolitinib Phosphate Brand 27 $450,524
Sprycel Dasatinib Brand 20 $271,163
Ibrance Palbociclib Brand 15 $247,213
Tavalisse Fostamatinib Disodium Brand 13 $193,403
Calquence Acalabrutinib Maleate Brand 14 $185,879
Eliquis Apixaban Brand 178 $137,177
Xarelto Rivaroxaban Brand 65 $63,121

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$7,326

Medicare's payments for the services billed

Medicare patients

75

Average age 76

Services billed

82

44 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 35%
Cancer 35%
Chronic kidney disease 31%
Ischemic heart disease 29%
Heart failure 27%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 72 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JAKAFI
  • Incyte Corporation $190
$190 27 —
ENHERTU
  • Daiichi Sankyo Inc. $117
  • AstraZeneca Pharmaceuticals LP $58
$175 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $144
$144 — —
REBLOZYL
  • E.R. Squibb & Sons, L.L.C. $120
$120 — —
BRUKINSA
  • BeiGene USA, Inc. $110
$110 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 72 with Patron

Records

512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record